지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 저널정보
- 한국병원약사회 병원약사회지 병원약사회지 제38권 제4호
- 발행연도
- 2021.11
- 수록면
- 429 - 438 (10page)
- DOI
- 10.32429/jkshp.2021.38.4.001
이용수
초록· 키워드
오류제보하기
Background : The conventional four-times-daily intravenous conditioning regimen of busulfan for hematopoietic stem cell transplantation (HSCT) has shown limitations, such as low patient compliance, inconvenient preparation and administration, and stability. In this study, we compared the efficacy and safety between four-times-daily regimen of busulfan and once-a-day regimen of busulfan in adult patients undergoing allogeneic HSCT.
Methods : We retrospectively analyzed the electronic medical records until September 2019 of patients who were administered busulfan once a day (ivBU1 group) and four times daily (ivBU4 group) between January 2016 to December 2016. Primary outcomes were 1-year survival, disease-free survival, relapse rate, non-relapse mortality, the incidence of graft-versus-host disease (GVHD), and neutrophil and platelet recovery time. The secondary outcomes were cytomegalovirus (CMV) infection and veno-occlusive disease (VOD) incidence.
Results : Comparison of the ivBU1 group (n=75) and the ivBU4 group (n=59) showed that the 1-year survival rate was 75.1% vs 62.6% (p=0.127) and the 1-year disease free survival rate was 62.4% vs 56.2% (p=0.736), respectively. There was no significant difference in multivariate analysis of the relapse rate adjusted by HLA (human leukocyte antigen) match and the type of transplantation (p=0.129). In terms of the non-relapse mortality rate, the ivBU1 group showed a significantly lower rate in the multivariate analysis than the ivBU4 group (13.5% vs 29.8%, p=0.025). The incidence of GVHD was also lower in the ivBU1 group regardless of the patient characteristics (Odds Ratio= 0.333, 95%CI 0.130-0.851, p=0.022).
There were no significant differences in neutrophil and platelet recovery, CMV infection, and VOD incidence.
Conclusion : There were no significant differences in survival, disease-free survival, and relapse rate according to the number of busulfan administrations, and non-relapse mortality and GVHD incidence were lower in the ivBU1 group. Based on the results of this study, it is expected that the once-daily method can replace the four-times-daily method.
목차
등록된 정보가 없습니다.
참고문헌 (17)
참고문헌 신청
Chhabra A / 2016 / Hematopoietic stem cell transplantation in immunocompetent hosts without radiation or chemotherapy / Science translational medicine 8(351):351ra105
Kim SW / 2009 / Busulfex (i.v. BU) and CY regimen before SCT: Japanese-targeted phase II pharmacokinetics combined study / Bone marrow transplantation 43(8):611~617
Kako S / 2018 / Safety and Efficacy of Once-Daily Intravenous Busulfan in Allogeneic Transplantation : A Matched-Pair Analysis / Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 24(10):2139~2144
Santos GW / 1983 / Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide / The New England journal of medicine 309(22):1347~1353
Hassan M / 1994 / Busulfan bioavailability / Blood 84(7):2144~2150
Kim SW / 2009 / Busulfex (i.v. BU) and CY regimen before SCT: Japanese-targeted phase II pharmacokinetics combined study / Bone marrow transplantation 43(8):611~617
Kako S / 2018 / Safety and Efficacy of Once-Daily Intravenous Busulfan in Allogeneic Transplantation : A Matched-Pair Analysis / Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 24(10):2139~2144
Santos GW / 1983 / Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide / The New England journal of medicine 309(22):1347~1353
Hassan M / 1994 / Busulfan bioavailability / Blood 84(7):2144~2150
함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Reduced-Intensity Conditioning with Busulfan and Fludarabine for Allogeneic Hematopoietic Stem Cell Transplantation in Acute Lymphoblastic Leukemia
Yonsei Medical Journal
2020 .01
-
Wiskott-Aldrich 증후군에서 조혈모세포이식
Clinical Pediatric Hematology-Oncology
2018 .01
-
The Effect of Dose Dependent treatment of Busulfan on Canine Testis
한국실험동물학회 학술발표대회 논문집
2017 .08
-
Allogeneic hematopoietic stem cell transplantation in congenital hemoglobinopathies with myeloablative conditioning and rabbit anti-thymocyte globulin
Blood Research
2018 .01
-
Favorable outcomes with durable chimerism after hematopoietic cell transplantation using busulfan and fludarabine-based reduced-intensity conditioning for pediatric patients with hemophagocytic lymphohistiocytosis
Blood Research
2022 .06
-
An Elevated Platelet Count Increases the Risk of Relapse in Ulcerative Colitis Patients with Mucosal Healing
Gut and Liver
2018 .01
-
Effects of immune system cells in GvHD and corresponding therapeutic strategies
Blood Research
2023 .03
-
Treatment Outcomes in Children and Adolescents with Relapsed or Progressed Solid Tumors: a 20-year, Single-Center Study
Journal of Korean Medical Science
2018 .01
-
Outcome of Intensive Therapy for Children with Relapsed Acute Myeloid Leukemia: A Single Institution Korean Study
Cancer Research and Treatment
2022 .10
-
Isolated Breast Relapse of Early T-Cell Precursor Acute Lymphoblastic Leukemia after Stem Cell Transplantation: A Pediatric Case and Literature Review
Clinical Pediatric Hematology-Oncology
2022 .04
-
Association of FOXP3 Single Nucleotide Polymorphisms With Clinical Outcomes After Allogenic Hematopoietic Stem Cell Transplantation
Annals of Laboratory Medicine
2018 .01
-
Ten-Year Trends of Hematopoietic Stem Cell Transplantation in Korean Pediatric Cancer from the National Health Insurance Claims Data
Cancer Research and Treatment
2024 .01
-
Efficient T cell engraftment in busulfan treated hPBMC-NIG mice
한국실험동물학회 학술발표대회 논문집
2022 .01
-
Clinical outcome of 1,000 consecutive cases of liver transplantation : a single center experience
Annals of Surgical Treatment and Research
2018 .11
-
Clinical Experience of Allogeneic Hematopoietic Stem Cell Transplantation in Elderly Patients Aged 60 Years and Older in South Korea
Yonsei Medical Journal
2023 .02
-
Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2015
Cancer Research and Treatment
2018 .01
-
Allogeneic clonal mesenchymal stem cell therapy for refractory graft-versus-host disease to standard treatment: a phase I study
The Korean Journal of Physiology & Pharmacology
2016 .01
-
Treatment and clinical outcomes of patients relapsing after allogeneic hematopoietic cell transplantation for myelodysplastic syndrome
Blood Research
2018 .01
-
Transplantation of human umbilical cord blood CD34+ cells into the liver of newborn NOD/SCID/IL-2Rγ null (NSG) mice after busulfan conditioning
Blood Research
2017 .01
이 논문의 저자 정보
최근 본 자료
댓글(0)
0